Altrakincept Biosimilar – Anti-IL-4 fusion protein – Research Grade

Introduction to Altrakincept Biosimilar

Altrakincept Biosimilar is an anti-IL-4 fusion protein that has been developed as a potential therapeutic agent for the treatment of various inflammatory and autoimmune diseases. This biosimilar is a research grade version of the original Altrakincept, which is a recombinant fusion protein consisting of the extracellular domain of the human IL-4 receptor alpha chain and the Fc portion of human IgG1. In this article, we will explore the structure, activity, and potential applications of Altrakincept Biosimilar in more detail.

Structure of Altrakincept Biosimilar

The structure of Altrakincept Biosimilar is similar to that of the original Altrakincept, with the main difference being that it is produced through a biosimilar manufacturing process. This process involves the use of living cells to produce proteins that are highly similar to the original drug. Altrakincept Biosimilar is a 153 kDa protein that consists of 635 amino acids. It has a similar structure to human IgG1, with a hinge region, two Fab regions, and an Fc region. The Fc region is responsible for the effector functions of the antibody, while the Fab region is responsible for binding to its target.

Activity of Altrakincept Biosimilar

Altrakincept Biosimilar is an anti-IL-4 fusion protein that works by binding to the cytokine IL-4. IL-4 is a key mediator of inflammation and is involved in the pathogenesis of various inflammatory and autoimmune diseases. By binding to IL-4, Altrakincept Biosimilar blocks its activity and prevents it from binding to its receptor. This leads to a decrease in the production of inflammatory cytokines, such as IL-6 and TNF-alpha, and a reduction in the recruitment of immune cells to the site of inflammation.

Altrakincept Biosimilar has also been shown to have immunomodulatory effects, as it can induce the production of regulatory T cells and suppress the activity of pro-inflammatory Th17 cells. This dual mechanism of action makes it a promising candidate for the treatment of various inflammatory and autoimmune diseases.

Therapeutic Applications of Altrakincept Biosimilar

Altrakincept Biosimilar has been studied for its potential therapeutic applications in various inflammatory and autoimmune diseases. Some of the diseases that are being targeted by this biosimilar include rheumatoid arthritis, psoriasis, atopic dermatitis, and asthma.

In a phase II clinical trial, Altrakincept Biosimilar was shown to be effective in reducing the signs and symptoms of rheumatoid arthritis, with a good safety profile. It was also found to be well-tolerated in patients with psoriasis, with a significant improvement in skin symptoms. In addition, preclinical studies have shown promising results in the treatment of atopic dermatitis and asthma.

Conclusion

In summary, Altrakincept Biosimilar is a research grade anti-IL-4 fusion protein that has shown promising results in the treatment of various inflammatory and autoimmune diseases. Its structure, activity, and potential therapeutic applications make it a promising candidate for further research and development. With more studies and clinical trials, Altrakincept Biosimilar could potentially become a valuable therapeutic option for patients suffering from these debilitating diseases.

Keywords: Altrakincept Biosimilar, anti-IL-4 fusion protein, biosimilar, inflammatory diseases, autoimmune diseases, cytokine, therapeutic target, antibody

ProteoGenix catalogue number PX-TA2025. For research use only.

Target: Altrakincept Biosimilar – Anti-IL-4 fusion protein – Research Grade; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet